Dr. Drilon on Immunotherapy in Lung Cancer

Alexander Drilon, MD
Published: Tuesday, Mar 28, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with lung cancer.

Not every patient is going to benefit from immunotherapy, explains Drilon. Data have recently been discovered that the likelihood of response to single-agent immune checkpoint inhibitors in EGFR-mutant and ALK-rearranged lung cancers is relatively low.

These low response rates could be because the tumors that harbor a driver may be more naïve and possibly less visible to the immune system, states Drilon. In clinical trials, the same level of response is not being seen in the patients who have a more substantial smoking history and who don’t have EGFR, ALK, or high PD-L1 staining.
 


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with lung cancer.

Not every patient is going to benefit from immunotherapy, explains Drilon. Data have recently been discovered that the likelihood of response to single-agent immune checkpoint inhibitors in EGFR-mutant and ALK-rearranged lung cancers is relatively low.

These low response rates could be because the tumors that harbor a driver may be more naïve and possibly less visible to the immune system, states Drilon. In clinical trials, the same level of response is not being seen in the patients who have a more substantial smoking history and who don’t have EGFR, ALK, or high PD-L1 staining.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x